No. 300China
Zhu Yi
Pharmaceuticals · Chengdu, Sichuan
Net worth
$11.5B
Today
−$148M−1.27%Past month
+$1.3B+12.48%As of Nov 11, 2026, 1:50 PM EST
Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments. The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024. Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide. Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
Net worth over time
+12.48%+$1.3B over the past month
$12B$11B$10B
Oct 12Nov 11
Principal holdings
1 positions| Company | Industry | Share | Value |
|---|---|---|---|
Sichuan Biokin Pharmaceutical SHANGHAI: 688506-CN | Healthcare | 100.0% | $11.5B |
Also known for
- Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.